{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:10Z","timestamp":1791179170825,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10637-015-0206-x","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T01:19:18Z","timestamp":1421716758000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia"],"prefix":"10.1007","volume":"33","author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Leli\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Depil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,21]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"206_CR2","first-page":"47","volume":"7","author":"K Ververis","year":"2013","unstructured":"Ververis K, Hiong A, Karagiannis TC, Licciardi PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7:47\u201360","journal-title":"Biologics"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1188\/13.CJON.34-40","volume":"17","author":"E Glass","year":"2013","unstructured":"Glass E, Viale PH (2013) Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 17:34\u201340","journal-title":"Clin J Oncol Nurs"},{"key":"206_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","volume":"280","author":"VM Richon","year":"2009","unstructured":"Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201\u2013210","journal-title":"Cancer Lett"},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247\u20131252","journal-title":"Oncologist"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631\u2013636","journal-title":"J Clin Oncol"},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1517\/13543784.2010.504710","volume":"19","author":"T Watanabe","year":"2010","unstructured":"Watanabe T (2010) Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19:1113\u20131127","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 1","key":"206_CR8","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1007\/s10637-010-9588-y","volume":"28","author":"D Buglio","year":"2010","unstructured":"Buglio D, Younes A (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 28(Suppl 1):S21\u2013S27","journal-title":"Invest New Drugs"},{"key":"206_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/107327481201900105","volume":"19","author":"M Veliz","year":"2012","unstructured":"Veliz M, Pinilla-Ibarz J (2012) Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 19:37\u201353","journal-title":"Cancer Control"},{"key":"206_CR10","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/1078-0432.CCR-08-2714","volume":"15","author":"G Lopez","year":"2009","unstructured":"Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G et al (2009) Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15:3472\u20133483","journal-title":"Clin Cancer Res"},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-05-0442","volume":"5","author":"JJ Buggy","year":"2006","unstructured":"Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L et al (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5:1309\u20131317","journal-title":"Mol Cancer Ther"},{"key":"206_CR12","doi-asserted-by":"crossref","unstructured":"Rivera-Del VN, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M et al (2010) PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol 207420","DOI":"10.1155\/2010\/207420"},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00280-010-1344-7","volume":"67","author":"C Yang","year":"2011","unstructured":"Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 67:439\u2013446","journal-title":"Cancer Chemother Pharmacol"},{"key":"206_CR14","first-page":"1115","volume":"31","author":"C Yang","year":"2011","unstructured":"Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al (2011) Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 31:1115\u20131123","journal-title":"Anticancer Res"},{"key":"206_CR15","unstructured":"National Cancer Institute. Common terminology criteria for adverse events. Version 3.0. NCI 2006; http:\/\/ctep.cancer.gov. Accessed 2-4-2013."},{"key":"206_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"206_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"206_CR18","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"206_CR19","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.ejca.2013.05.009","volume":"49","author":"S Fouliard","year":"2013","unstructured":"Fouliard S, Robert R, Jacquet-Bescond A, du Rieu QC, Balasubramanian S, Loury D et al (2013) Pharmacokinetic\/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454\/PCI-24781) in phase I. Eur J Cancer 49:2791\u20132797","journal-title":"Eur J Cancer"},{"key":"206_CR20","unstructured":"EMA Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency 2010; www.ema.europa.eu. Accessed 30-9-2013"},{"key":"206_CR21","unstructured":"Fouliard S, Chenel M. BSA-adjusted dose? An old method to fight old bias. Poster presented at the Population Approach Group Europe meeting 2010. PAGE 2010; www.page-meeting.org. Accessed 30-9-2013"},{"key":"206_CR22","doi-asserted-by":"crossref","unstructured":"Evens AM, Vose JM, Harb W, Gordon LI, Langdon R, Grant B et al. A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed\/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL). Abstract 55. Blood 2013; 120 (Suppl)","DOI":"10.1182\/blood.V120.21.55.55"},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","volume":"121","author":"MR Green","year":"2013","unstructured":"Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al (2013) Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121:1604\u20131611","journal-title":"Blood"},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C et al (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46:176\u2013181","journal-title":"Nat Genet"},{"key":"206_CR25","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/bjc.2011.156","volume":"104","author":"PN Munster","year":"2011","unstructured":"Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A et al (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104:1828\u20131835","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0206-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0206-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:03:00Z","timestamp":1678510980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0206-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,21]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0206-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,21]]},"assertion":[{"value":"30 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}